In summary, we suggest that although ARID1A is not frequently mutated and well-studied in prostate cancer, it may be one of the important factors in tumorigenesis of prostate tumors and may act as a potential biomarker for this cancer. This evidence concerns the gene ARID1A and prostate neoplasm.